Coherus Oncology, Inc.

Coherus Oncology is a biopharmaceutical company headquartered in Redwood City, California, that develops immunotherapies and biosimilar products for oncology and inflammatory disease indications. The company's commercial portfolio includes UDENYCA, a biosimilar to Neulasta used in cancer supportive care; YUSIMRY, a biosimilar to Humira for inflammatory conditions such as rheumatoid arthritis and Crohn's disease; and CIMERLI, a Lucentis biosimilar for retinal diseases. Its oncology pipeline comprises several investigational candidates, including LOQTORZI, a next-generation PD-1 inhibitor; Casdozokitug, an IL-27-targeting monoclonal antibody; CHS-114, an afucosylated IgG1 antibody targeting tumor-infiltrating regulatory T cells; and CHS-1000, an anti-ILT4 monoclonal antibody for solid tumors.

The company operates a dual-focused business model combining marketed biosimilar products with proprietary immunotherapy development. Its pipeline incorporates collaborations with partners including Junshi Biosciences for toripalimab co-development and licensing arrangements with multiple entities including Genentech and GlaxoSmithKline. The company maintains a relatively lean operational footprint with approximately 158 full-time employees and operates primarily in the United States market, though its partnerships extend to international collaborators.